Neurocrine Biosciences, Inc.
NBIX
$118.78
$1.911.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 572.60M | 627.70M | 622.10M | 590.20M | 515.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 572.60M | 627.70M | 622.10M | 590.20M | 515.30M |
| Cost of Revenue | 272.40M | 194.90M | 203.00M | 200.30M | 166.90M |
| Gross Profit | 300.20M | 432.80M | 419.10M | 389.90M | 348.40M |
| SG&A Expenses | 276.50M | 301.80M | 234.30M | 242.00M | 243.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 548.90M | 496.70M | 437.30M | 442.30M | 410.00M |
| Operating Income | 23.70M | 131.00M | 184.80M | 147.90M | 105.30M |
| Income Before Tax | 14.70M | 162.60M | 190.30M | 98.60M | 34.50M |
| Income Tax Expenses | 6.80M | 59.50M | 60.50M | 33.60M | -8.90M |
| Earnings from Continuing Operations | 7.90M | 103.10M | 129.80M | 65.00M | 43.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.90M | 103.10M | 129.80M | 65.00M | 43.40M |
| EBIT | 23.70M | 131.00M | 184.80M | 147.90M | 105.30M |
| EBITDA | 31.30M | 138.10M | 191.30M | 155.20M | 111.50M |
| EPS Basic | 0.08 | 1.03 | 1.28 | 0.64 | 0.43 |
| Normalized Basic EPS | 0.28 | 0.96 | 1.29 | 1.06 | 0.80 |
| EPS Diluted | 0.08 | 1.00 | 1.24 | 0.63 | 0.42 |
| Normalized Diluted EPS | 0.28 | 0.93 | 1.25 | 1.03 | 0.77 |
| Average Basic Shares Outstanding | 99.70M | 100.00M | 101.10M | 100.80M | 99.80M |
| Average Diluted Shares Outstanding | 102.50M | 102.90M | 104.30M | 103.90M | 103.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |